Intellia announces positive two-year Phase 1 data for nex-z in ATTRv-PN with durable TTR reduction

Intellia Therapeutics, Inc.

Mean serum TTR reduction of 90% by Day 28 remained virtually unchanged for at least 24 months in 33 patients.
14 of 18 patients showed clinically meaningful improvement (≥4 points) on mNIS+7 at 24 months.
5 of 6 patients previously on patisiran and progressing achieved improvement on mNIS+7 at 24 months.
Enrollment progressing well in Phase 3 MAGNITUDE-2 trial for ATTRv-PN; potential BLA submission by 2028.
No new drug-related adverse events; most common were mild-to-moderate infusion reactions with no discontinuations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.